有氧运动干预非酒精性脂肪性肝病的血清代谢组学研究

肝脏 ›› 2024, Vol. 29 ›› Issue (5): 571-575.

有氧运动干预非酒精性脂肪性肝病的血清代谢组学研究

袁乙富, 杜晟楠, 张思敏, 曹勤, 蒋元烨

200062 上海中医药大学附属普陀医院消化内科(袁乙富,杜晟楠,曹勤,蒋元烨);教育规培科(张思敏)

收稿日期:2023-05-28 出版日期:2024-05-31 发布日期:2024-08-28
通讯作者: 蒋元烨,Email:yuanye1014@126.com;曹勤,Email:caoqin434@sina.com
基金资助:
上海市自然科学基金(22ZR1455900);上海市卫计委临床研究专项面上项目(201940449);上海市普陀区卫生健康系统科技创新项目重点项目(ptkwws202201);上海中医药大学后备卓越中医人才项目(20D-RC-02);上海市名中医沈红权普陀传承工作室(ptzygzs2201,SHGZS-202224);上海市普陀区杏林优青人才培养计划(ptxlyq2201);上海市普陀区卫生健康系统特色专病建设项目(2023tszb01)

Exploring the Serum metabonomic profile of aerobic exercise intervention in non-alcoholic fatty liver Disease

YUAN Yi-fu¹, DU Sheng-nan¹, ZHANG Si-min², CAO Qin¹, JIANG Yuan-ye¹

1. Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China;
2. Department of Education Planning and Training, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China

Received:2023-05-28 Online:2024-05-31 Published:2024-08-28
Contact: JIANG Yuan-ye,Email:yuanye1014@126.com; CAO Qin,Email:caoqin434@sina.com

摘要/Abstract

摘要： 目的探讨有氧运动干预4周前后非酒精性脂肪肝病(NAFLD)患者临床特征及血清代谢产物变化。方法选择2021年6月—2022年6月上海市普陀区中心医院消化内科门诊诊断为NAFLD的患者20例作为研究对象,采用有氧运动进行干预。收集患者基本信息、肝生化、血脂指标,同时测定血清样本代谢产物的变化,分析干预前后差异性代谢产物。结果 NAFLD患者体质量由干预前(72.21±7.44) kg下降至(70.63±7.25) kg;BMI由(25.39±1.32 )kg/m² 下降至(24.83±1.39) kg/m²;腰围由原来的(96.52±6.61) cm降至(93.76±6.23) cm,差异均具有统计学意义(P<0.05);ALT、AST、AKP及GGT和CHE干预后分别为[21.00 (17.00, 25.00) 、13.00 (9.00, 19.50) 、68.32±24.14、18.00 (14.50, 35.50) 、(6466.92±1402.02) U/L]较干预前显著下降,差异具有统计学意义(P<0.05)。TG及LDL干预后分别为[1.14 (1.05, 1.48) mmol/L、(2.48±0.57 )mmol/L]较干预前显著下降,差异具有统计学意义(P<0.05)。血清代谢组学鉴定到31种潜在的差异代谢物,大部分为脂类及氨基酸类。结论有氧运动干预可以减轻NAFLD患者的体质量,改善血生化指标,同时改善NAFLD患者脂质及氨基酸代谢,从而有效减缓NAFLD的进展。这对于为NAFLD患者制定合理运动治疗方案有着重要临床意义。

关键词: 有氧运动, 非酒精性脂肪肝, 血清代谢组学

Abstract: Objective To investigate the alteraions in clinical characteristics and serum metabolites in patients with non-alcoholic fatty liver disease (NAFLD) following a four-week aerobic exercise intervention. Methods 20 patients with NAFLD, diagnosed at the Department of Gastroenterology at Putuo District Central Hospital, Shanghai, from June 2021 to June 2022, underwent an aerobic exercise regimen. We collected baseline patients data, liver function tests, and blood lipid profiles. Concurrently, serum sample metabolites were measured, and the metabolic differences pre-and post-intervention were analyzed. Results In patients with NAFLD, significant reductions were observed post-intervention: body weight decreased from 72.21 ± 7.44 kg to 70.63 ± 7.25 kg; BMI dropped from 25.39 ± 1.32 kg/m² to 24.83 ± 1.39 kg/m²; and waist circumference from 96.52 ± 6.61 cm to 93.76 ± 6.23 cm (P<0.05); Post-intervention, liver enzymes showed marked improvements with ALT, AST, AKP, GGT, and CHE levels at [21.00 (17.00, 25.00) U/L, 13.00 (9.00, 19.50) U/L, 68.32 ± 24.14 U/L, 18.00 (14.50, 35.50) U/L, 6466.92 ± 1402.02 U/L] respectively, all significantly lower than pre-intervention values (P<0.05). Additionally, significant decreases were noted in TG and LDL levels[1.14 (1.05, 1.48) mmol/L, 2.48 ± 0.57 mmol/L] respectively(P<0.05). Serum metabolomics analysis identified 31 potential differential metabolites, predominantly lipids and amino acids. Conclusion Aerobic exercise intervention has been shown to effectively reduce body weight, improve blood biochemical indices, and enhance lipid and amino acid metabolism in patients with NAFLD. These improvements can significantly decelerate the progress of NAFLD. This underscores the clinical importance of devising tailored exercise therapy plans for NAFLD patients.

Key words: Aerobic exercise, Non-alcoholic fatty liver, Serum metabolomics

袁乙富, 杜晟楠, 张思敏, 曹勤, 蒋元烨. 有氧运动干预非酒精性脂肪性肝病的血清代谢组学研究[J]. 肝脏, 2024, 29(5): 571-575.

YUAN Yi-fu, DU Sheng-nan, ZHANG Si-min, CAO Qin, JIANG Yuan-ye. Exploring the Serum metabonomic profile of aerobic exercise intervention in non-alcoholic fatty liver Disease[J]. Chinese Hepatolgy, 2024, 29(5): 571-575.

/ 推荐

参考文献

[1] Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2021,18(4):223-238.
[2] Jarvis H, Craig D, Barker R, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies[J]. PLoS Med,2020,17(4):e1003100.
[3] Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia,1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019,4(5):389-398.
[4] Younossi ZM, Corey KE, Lim JK. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review[J]. Gastroenterology,2021,160(3):912-918.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 临床肝胆病杂志,2018,34(5):947-957.
[6] Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. J Hepatol,2012,57(1):157-166.
[7] Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review[J]. J Hepatol,2017,66(1):142-152.
[8] Zelber-Sagi S, Buch A, Yeshua H, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial[J]. World J Gastroenterol,2014,20(15):4382-4392.
[9] Furlani IL, da Cruz Nunes E, Canuto GAB, et al. Liquid Chromatography-Mass Spectrometry for Clinical Metabolomics: An Overview[J]. Adv Exp Med Biol,2021,1336:179-213.
[10] Yang Y, Huang Z, Yang Z, et al. Serum metabolomic profiling reveals an increase in homocitrulline in Chinese patients with nonalcoholic fatty liver disease: a retrospective study[J]. PeerJ,2021,9: e11346.
[11] Tomita K, Teratani T, Yokoyama H, et al. Plasma free myristic acid proportion is a predictor of nonalcoholic steatohepatitis[J]. Dig Dis Sci,2011,56(10):3045-3052.
[12] Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis[J]. Hepatology,2011,54(3):837-845.
[13] Rom O, Liu Y, Liu Z, et al. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome[J]. Sci Transl Med,2020,12(572):eaaz2841.
[14] Gaggini M, Carli F, Rosso C, et al. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance[J]. Hepatology,2018,67(1):145-158.
[15] Yamakado M, Tanaka T, Nagao K, et al. Plasma amino acid profile associated with fatty liver disease and co-occurrence of metabolic risk factors[J]. Sci Rep,2017,7(1):14485.
[16] 孙亚新. 基于代谢组学技术的二甲双脈对双酚A诱导大鼠肝损伤的保护作用机制研究. 郑州大学,2020.
[17] Zouhal H, Jayavel A, Parasuraman K, et al. Effects of Exercise Training on Anabolic and Catabolic Hormones with Advanced Age: A Systematic Review[J]. Sports Med,2022,52(6):1353-1368.
[18] Sarkar M, VanWagner LB, Terry JG, et al. Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife.[J]. Am J Gastroenterol,2019,114(5):758-763.
[19] Jaruvongvanich V, Sanguankeo A, Riangwiwat T, et al. Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis[J]. Ann Hepatol,2017,16(3):382-394.
[20] Dhindsa S, Ghanim H, Batra M, et al. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes[J]. Diabetes Care,2016,39(1):82-91.